Characterization of the binding of and the immune response to pneumococcal group 9 capsular polysaccharides.

Mol Immunol

Department of Microbiology, School of Medicine and Health Sciences, George Washington University, Washington, DC 20037.

Published: May 1987

The binding of Streptococcus pneumoniae 14C-9N and 14C-9V polysaccharides (PSs) to lymphocytes and polymorphonuclear leukocytes of human blood were studied. The quantity of 14C-9N and 14C-9V PSs bound to leukocytes was proportional to the number of leukocytes and the incubation time; the binding was temperature-dependent. The binding activity appeared to be specific, since the binding was inhibited by prior treatment with homologous group 9 PSs. The binding was also inhibited by prior treatment with cross-reactive group 9 PSs. The binding of 14C-9V PS to leukocytes was greater than that of 14C-9N PS. Reciprocal plot analysis revealed 6.4 X 10(4) binding sites for 9N PS on each lymphocyte and 9.5 X 10(4) binding sites for 9V PS on each lymphocyte, while the affinity constant for 9N PS was 3.7 X 10(9) M-1 and that for 9V PS was 9.4 X 10(8) M-1. Furthermore, there were 7.8 X 10(4) binding sites for 9N PS on each polymorphonuclear leukocyte and 1.2 X 10(5) binding sites for 9 V PS on each polymorphonuclear leukocyte, while the affinity constant for 9N PS was 1.6 X 10(9) M-1 and that for 9V PS was 8.5 X 10(8) M-1. There was a high degree of inhibition of the binding of 14C-9N PS to leukocytes by prior treatment with 9V PS, and a low degree of inhibition of the binding of 14C-9V PS to leukocytes by prior treatment with 9N PS. The high degree of inhibition of binding of 9V PS to leukocytes was not directly related to the production of cross-reactive antibodies to 9N PS. The serum antibody and the plaque-forming cell responses in mice immunized with 9V PS were significantly greater than responses in mice immunized with 9N PS.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0161-5890(87)90016-2DOI Listing

Publication Analysis

Top Keywords

prior treatment
16
binding sites
16
binding
13
104 binding
12
degree inhibition
12
inhibition binding
12
14c-9n 14c-9v
8
binding inhibited
8
inhibited prior
8
group pss
8

Similar Publications

Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature.

Curr Drug Saf

January 2025

National Center Chalbi Belkahia of Pharmacovigilance, Department of Collection and Analysis of Adverse Effects, Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine, Research unit: UR17ES12, Tunis, Tunisia.

Background: Trimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association.

View Article and Find Full Text PDF

My Bad, You Got This: witnessing, therapist attitude and the synergy between psychedelics and inner healing intelligence in the treatment of trauma.

Front Psychol

January 2025

Department of Psychiatry, Tufts University School of Medicine, Maine Medical Center, Maine Track Program, Boston, MA, United States.

The MAPS (Multidisciplinary Association for Psychedelic Studies) sponsored MDMA-assisted therapy protocol has had greater success in treating trauma in preliminary clinical trials than any prior psychotherapeutic, pharmacologic, or combined approach. It is predicated on a synergy between drug action and the participant's inner healing intelligence. The latter is described mainly by analogy with the body's capacity to heal itself, and the treatment is characterized as a means of activating or accessing this capacity.

View Article and Find Full Text PDF

Objective: Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC.

Methods And Analysis: In this phase II single-stage Fleming design, patients with SGC with a progressive disease progression within 6 months prior to entering the study, were divided into ACC (adenoid cytic carcinoma) and non-ACC.

View Article and Find Full Text PDF

Purpose Of Review: We present current evidence on the associations among sleep, pain, and medications for opioid use disorder (MOUD) among individuals with opioid use disorder (OUD).

Recent Findings: We searched MEDLINE, Embase, PsycInfo, Web of Science, and Cochrane Library from inception until September 2023 for original research studies examining sleep, pain, and MOUD. We identified 19 manuscripts (14 were cross-sectional studies, four were prospective cohort studies, and one was a randomized controlled trial).

View Article and Find Full Text PDF

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.

Alzheimers Dement (Amst)

January 2025

Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC Amsterdam The Netherlands.

Introduction: Blood-based glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) have shown promising prognostic potential in Alzheimer's disease (AD), but their applicability in clinical settings where comorbidities are prevalent remains uncertain.

Methods: Simoa assays quantified GFAP, NfL, and pTau181 in retrospectively retrieved prediagnostic serum samples from 102 AD patients and 21 non-AD controls.

Results: Higher serum GFAP levels predicted earlier clinical presentation and faster subsequent Mini-Mental State Examination decline in AD patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!